Jul 2, 2026
•
3 min read
It's a loss leader. You're judging it like a profit centre.
Jun 26, 2026
8 min read
One ignores LTV and demands profit on day one. The other loses money upfront to win big later. Both are right. Here's the discipline underneath that decides who scales.
Jun 15, 2026
12 min read
Loyalty is not a programme. It is a prescription.
Jun 5, 2026
The case for founder-led is not about trust or vanity. It is about the cheapest top of funnel you will ever own, the tax you have to pay to earn it, and the grid you have to build before it kills you.
May 29, 2026
10 min read
How RULE OF ONETM turns a prescriptive supplement brand into a £50M revenue machine, with the subscriber math, retention curves, and acquisition engine that make a 9-10x EBITDA multiple real.
May 23, 2026
The exit math, capital roadmap, and operating system behind £100M supplement exits — without retail or reckless dilution.
May 15, 2026
What Haaland, Pep Guardiola, and an 80-year-old woman at the Etihad taught me about real operating leverage, invisible systems, and building brands people feel in their bones.
May 8, 2026
13 min read
Why most UK consumer brands stall at £150m and the playbook the next four are running to cross £1bn
May 1, 2026
9 min read
Most CPG founders run all three. None deeply enough to matter. Pick one. Build the architecture underneath it. Resist the temptation to add the others until the first one is compounding.
Apr 23, 2026
London Nootropics had the head start. Dirtea and Spacegoods had the worldview. Here is why that difference decided the category.
Apr 16, 2026
The model was brilliant. The methods were not. Both things are true — and both are worth understanding.
Apr 9, 2026
16 min read
Chad Janis didn't build a better supplement. He built the fastest exit in CPG history. Here is how the system worked.
